Tuesday, February 7, 2023

561.316.3330

Biotechnology News Magazine

iOnctura Awarded EUR17.5 Mil Funding from the EIC Accelerator for Clinical Development of Novel Pancreatic Cancer Therapy

Funding will support iOnctura’s clinical program for IOA-289, a first-in-class autotaxin inhibitor for the treatment of cancer

Latest Posts

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and...

NTX1088 is a First-in-Class and highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors.

TransCure bioServices Offers BioVolume 3D Imaging for Insightful Preclinical Oncology Research

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width.

CLINUVEL Drug Significantly Reduces UV Skin Damage

“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.

Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, announces today that it has been granted EUR17.5 million funding from the European Investment Council’s (EIC) Accelerator Program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of EUR2.5 million, and EUR15 million of equity investment.

On 8 December 2022 iOnctura announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.

Catherine Pickering, Chief Executive Officer of iOnctura, said: “We are delighted to announce this funding from the EIC to support the clinical development of IOA-289 for the treatment of pancreatic cancer. Pancreatic cancer is the only cancer with mortality on the rise in both sexes and is currently the 3rd largest cause of death by cancer in the US, and the 4th in Europe.

“There’s an urgent need to develop new therapies for pancreatic cancer and preclinical data demonstrate that IOA-289 offers a new approach, through a multi-pronged mechanism that addresses three hallmarks of cancer: fibrosis, immune suppression and tumor cell proliferation.”

iOnctura was granted the maximum allowed funding in appreciation of the significant potential of IOA-289, a highly-selective, first-in-class autotaxin inhibitor, to transform the treatment of pancreatic cancer. The judging panel recognized its unique ability to simultaneously target independent tumor survival pathways associated with tumor proliferation, fibrosis and immune suppression.

Funding came as part of the most recent tranche of grants from the EIC Accelerator program under Horizon Europe, that aims to accelerate deep tech start-ups through grants and equity investments. For this second wave of grants, the European Commission selected 78 innovative start-ups for funding during a highly competitive process. In all, 240 companies were interviewed by juries of experienced investors and entrepreneurs out of a total of more than 1,000 applications. The selected companies will together receive up to EUR470 million of funding in a combination of grants and equity investments.

The Phase Ib AION-02 study (NCT05586516) is a dose-escalation study of IOA-289 in combination with standard-of-care gemcitabine/nab-paclitaxel chemotherapy in first-line metastatic pancreatic cancer.

 

 

 

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine